In terms of the 5-year EFS rate, RO+ MS-LCH patients were at 53.8% ± 9.6%, and RO− MS-LCH patients at 76.2% ± 14.8%, however, this too did not reach statistical significance ( χ 2 = 2.45, p = 0.118). 3.2.3.
← all excerpts
Clinical features and prognostic factors of pediatric Langerhans cell histiocytosis: a single-center retrospective study.
2
0.1180
0.1180
The sentences
As such, their role in LCH therapy may be significant.